IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC
ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

a 2022

IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS et. al.

Basic information

Original name

IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

Authors

BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN and K. DE VLAM

Edition

2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 27.400

RIV identification code

RIV/00216224:14160/22:00128084

Organization unit

Faculty of Pharmacy

ISSN

DOI

http://dx.doi.org/10.1136/annrheumdis-2022-eular.536

UT WoS

000850279000259

Keywords in English

Izokibep; ABY-035; psoriatic arthriris; clinical trial

Abstract

V originále

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA.

Citovat

BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ, A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN and K. DE VLAM. IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY. 2022. ISSN 0003-4967. Available from: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.

@proceedings{2247562,
   author = {Behrens, F. and Taylor, P. C. and Wetzel, D. and Brun, N. C. and BrandtandJuergens, J. and Drescher, E. and Dokoupilová, Eva and RowinskaandOsuch, A. and Martin, N. AbdelandKader and de Vlam, K.},
   doi = {http://dx.doi.org/10.1136/annrheumdis-2022-eular.536},
   keywords = {Izokibep; ABY-035; psoriatic arthriris; clinical trial},
   language = {eng},
   title = {IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY},
   url = {https://ard.bmj.com/content/81/Suppl_1/170},
   year = {2022}
}

TY  - CONF
ID  - 2247562
AU  - Behrens, F. - Taylor, P. C. - Wetzel, D. - Brun, N. C. - Brandt-Juergens, J. - Drescher, E. - Dokoupilová, Eva - Rowinska-Osuch, A. - Martin, N. Abdel-Kader - de Vlam, K.
PY  - 2022
TI  - IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
KW  - Izokibep
KW  - ABY-035
KW  - psoriatic arthriris
KW  - clinical trial
UR  - https://ard.bmj.com/content/81/Suppl_1/170
N2  - Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA.
ER  -

BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ, A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN and K. DE VLAM. \textit{IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY}. 2022. ISSN~0003-4967. Available from: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.

Detailed Information on Publication Record